Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

NCT06627244 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT06627244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06627244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Recruiting
Start date
February 14, 2025
Completion date
February 17, 2031
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma, metastatic uveal melanoma in the liver